Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives

Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with impro...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2017-01, Vol.9, p.299-306
Main Authors: El-Amm, Joelle, Nassabein, Rami, Aragon-Ching, Jeanny B
Format: Article
Language:English
Subjects:
Abiraterone
abiraterone acetate
Androgens
Biosynthesis
Cancer metastasis
Cancer therapies
Care and treatment
Chemotherapy
Clinical trials
Community support
Complications and side effects
Dosage and administration
Enzymes
FDA approval
Metastasis
metastatic castration-resistant prostate cancer
Oncology
Pain
Patient outcomes
patient-related outcomes
Patients
Prostate cancer
Quality of life
Questionnaires
Review
Studies
Survival analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with improvement in overall survival as well as secondary end points such as prostate-specific antigen (PSA) and radiographic response rates, time to PSA progression, and progression-free survival. There has been a lot of interest and emphasis in the evaluation of patient-related outcomes (PROs) as it relates to quality of life, pain, adverse events, fatigue, and among others, in the use of different agents that have been shown to improve survival. This review examines the companion PROs in conjunction with abiraterone acetate use. This is particularly relevant since PROs are increasingly viewed as a key metric for drug label claims in granting approval across regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency.
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S139305